Get startedLog in
    Picture of UCB SA logo

    UCB — UCB SA News Story

    0.000.00%
    be flag iconLast trade - 00:00
    HealthcareAdventurousLarge CapHigh Flyer
    All News

    Brief: UCB Gets Positive Results From GEMZ Phase 3 Study Of Fenfluramine

    Picture of UCB SA logoUCB SA
    27/06/2025 06:03
    June 27 (Reuters) - Ucb SA UCB.BR:

ANNOUNCES POSITIVE RESULTS FROM GEMZ PHASE 3 STUDY OF FENFLURAMINE IN CDKL5 DEFICIENCY DISORDER

PHASE 3 STUDY MET PRIMARY AND KEY SECONDARY CLINICAL ENDPOINTS

PLANS TO SUBMIT FOR REGULATORY APPROVAL TO BRING THIS POTENTIAL TREATMENT OPTION TO PEOPLE LIVING WITH CDD AS SOON AS POSSIBLE

Source text

Further company coverage: UCB.BR

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))

    Recent news on UCB SA

    See all news